Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages. Granules India Limited was founded in 1984 and is based in Hyderabad, India. The company has established itself as a prominent player in the pharmaceutical manufacturing sector with a vertically integrated business model that spans across the entire pharmaceutical value chain.
The Company has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs), and finished dosages (FDs). This comprehensive approach allows the company to maintain better control over quality, costs, and supply chain management while serving diverse customer needs across different segments of the pharmaceutical industry.
It has over seven manufacturing facilities, approximately six of which are located in India and one in the United States. This strategic geographical distribution of manufacturing facilities enables the company to serve both domestic and international markets effectively. The Company sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India.
The company's manufacturing excellence is demonstrated through its API portfolio, which includes key products such as Paracetamol, Metformin, Guaifenesin, and Methocarbamol APIs. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. The company also provides tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology.
The Company's wholly-owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited, and Granules Lifesciences Private Limited. This subsidiary structure allows the company to maintain a strong presence in key international markets while optimizing regulatory compliance and operational efficiency across different geographies.
Granules India has a Market Cap of ₹11,953 Crore as of recent data. The company has demonstrated financial resilience over the years, though it has faced some challenges in recent periods. Revenue: ₹4,482 Crore. Profit: ₹502 Crore for the recent financial year. Promoter Holding: 38.8% indicates strong promoter commitment to the business.
Recent quarterly performance shows mixed results with Granules India Ltd's revenue fell -1.11% since last year same period to ₹1,143.37 Crore in Q3 FY2024-2025. However, the company demonstrated some operational improvements with On a quarterly growth basis, Granules India Ltd has generated 17.89% jump in its revenue since last 3-months.
For Q4 FY25, the company showed positive momentum with Granules India Ltd's net profit jumped 17.26% since last year same period to ₹152.03 Crore in Q4 FY2024-2025. The company's ability to generate consistent profits despite market challenges demonstrates its operational resilience and strategic positioning in the pharmaceutical sector.
The company has been actively working on regulatory compliance and facility upgrades. Granules India's Bonthapally facility completed US FDA inspection with one 483 observation. Granules India's API Unit-I facility in Bonthapally received a single observation from the U.S. FDA after an inspection. The company has committed to addressing these observations promptly, demonstrating its commitment to maintaining regulatory standards.
Additionally, Granules India announced that its subsidiary Granules Pharmaceuticals Inc. received and resolved one observation from the USFDA during a pre-approval inspection at its Chantilly facility. These developments highlight the company's ongoing efforts to maintain compliance across its international operations.
The company is positioning itself for future growth with several strategic initiatives. Granules India is finalizing remediation at its Gagillapur facility, anticipating USFDA re-inspection. The company aims to launch 11 pending products in the US market and is preparing for its first major oncology product launch by FY28.
Despite recent challenges, analyst sentiment remains cautiously optimistic. Granules India reported weaker-than-expected revenue and profit figures, leading to revised EPS estimates. Despite challenges, a target price of INR 612 is maintained with a BUY rating. Granules India Ltd target price ₹621.62, a slight upside of 27.08% compared to current price of ₹490.8.
The company is listed on the Bombay Stock Exchange with the code 532482, and on the National Stock Exchange with the code GRANULES. This dual listing provides enhanced liquidity and accessibility for investors across different trading platforms. The company's stock is also part of various indices, reflecting its significance in the pharmaceutical sector.
Granules India represents a well-established pharmaceutical manufacturing company with a strong foundation in API manufacturing, global reach, and strategic positioning for future growth in the evolving pharmaceutical landscape. The company's vertically integrated model, diverse product portfolio, and commitment to regulatory excellence position it as a significant player in the Indian pharmaceutical industry.
